COVID-19: FDA’s Stenzel Talks Abbott Test, Future Clearances In Call
Timothy Stenzel, director of the Office of In Vitro Diagnostics and Radiological Health within the US agency's device center, offered an update on a controversial Abbott test and covered other issues during a COVID-19 developer webinar.
You may also be interested in...
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
The US FDA released updated safety information on Endologix Inc.’s AFX2 Endovascular abdominal aortic aneurysm (AAA) graft system on Tuesday. Previous devices in the product line have been associated with an increased risk of abnormal bleeding.
Radiofrequencies from the incontinence-sensing devices may interfere with other medical equipment in a hospital setting.